First Trust Advisors LP bought a new position in Omnicell Inc. (NASDAQ:OMCL) during the second quarter, Holdings Channel reports. The firm bought 21,809 shares of the company’s stock, valued at approximately $747,000. First Trust Advisors LP owned 0.06% of Omnicell at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Fisher Asset Management LLC raised its stake in shares of Omnicell by 1.0% in the second quarter. Fisher Asset Management LLC now owns 536,152 shares of the company’s stock worth $19,452,000 after buying an additional 5,152 shares during the period. Goldman Sachs Group Inc. raised its position in Omnicell by 62.9% in the first quarter. Goldman Sachs Group Inc. now owns 93,228 shares of the company’s stock valued at $2,598,000 after buying an additional 36,015 shares during the last quarter. Eagle Asset Management Inc. raised its position in Omnicell by 3.7% in the second quarter. Eagle Asset Management Inc. now owns 115,648 shares of the company’s stock valued at $3,958,000 after buying an additional 4,096 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in Omnicell by 105.4% in the second quarter. BNP Paribas Arbitrage SA now owns 11,522 shares of the company’s stock valued at $394,000 after buying an additional 5,913 shares during the last quarter. Finally, BlackRock Group LTD raised its position in Omnicell by 33.9% in the first quarter. BlackRock Group LTD now owns 56,209 shares of the company’s stock valued at $1,567,000 after buying an additional 14,243 shares during the last quarter. 95.26% of the stock is currently owned by institutional investors.
Shares of Omnicell Inc. (NASDAQ:OMCL) traded down 0.30% on Friday, reaching $36.79. The company’s stock had a trading volume of 165,963 shares. The company’s 50 day moving average is $37.88 and its 200-day moving average is $33.96. Omnicell Inc. has a 1-year low of $25.06 and a 1-year high of $40.50. The stock has a market cap of $1.33 billion, a PE ratio of 93.38 and a beta of 0.58.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.32 by $0.06. Omnicell had a return on equity of 10.41% and a net margin of 2.36%. The firm had revenue of $175.60 million for the quarter, compared to the consensus estimate of $170.89 million. During the same quarter last year, the business posted $0.28 EPS. The company’s revenue for the quarter was up 55.7% on a year-over-year basis. On average, equities analysts predict that Omnicell Inc. will post $1.58 earnings per share for the current fiscal year.
Several research analysts recently weighed in on OMCL shares. Sidoti lowered Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price target on the stock. in a research report on Thursday, September 8th. FBR & Co upped their price target on Omnicell from $35.00 to $40.00 and gave the company an “outperform” rating in a research report on Thursday, July 7th. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a research report on Wednesday, June 29th. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $46.00 price target on shares of Omnicell in a research report on Tuesday, September 13th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $38.13.
In related news, Chairman Randall A. Lipps sold 37,425 shares of Omnicell stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $37.37, for a total value of $1,398,572.25. Following the sale, the chairman now owns 192,325 shares of the company’s stock, valued at $7,187,185.25. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gary S. Petersmeyer sold 2,000 shares of Omnicell stock in a transaction dated Monday, September 12th. The shares were sold at an average price of $37.98, for a total value of $75,960.00. Following the completion of the sale, the director now directly owns 17,987 shares in the company, valued at approximately $683,146.26. The disclosure for this sale can be found here. 3.75% of the stock is owned by corporate insiders.
Omnicell Company Profile
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.